Literature DB >> 28724631

The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.

Ketan S Gajiwala1, Neil Grodsky2, Ben Bolaños2, Junli Feng2, RoseAnn Ferre2, Sergei Timofeevski3, Meirong Xu3, Brion W Murray3, Ted W Johnson2, Al Stewart2.   

Abstract

The receptor tyrosine kinase family consisting of Tyro3, Axl, and Mer (TAM) is one of the most recently identified receptor tyrosine kinase families. TAM receptors are up-regulated postnatally and maintained at high levels in adults. They all play an important role in immunity, but Axl has also been implicated in cancer and therefore is a target in the discovery and development of novel therapeutics. However, of the three members of the TAM family, the Axl kinase domain is the only one that has so far eluded structure determination. To this end, using differential scanning fluorimetry and hydrogen-deuterium exchange mass spectrometry, we show here that a lower stability and greater dynamic nature of the Axl kinase domain may account for its poor crystallizability. We present the first structural characterization of the Axl kinase domain in complex with a small-molecule macrocyclic inhibitor. The Axl crystal structure revealed two distinct conformational states of the enzyme, providing a first glimpse of what an active TAM receptor kinase may look like and suggesting a potential role for the juxtamembrane region in enzyme activity. We noted that the ATP/inhibitor-binding sites of the TAM members closely resemble each other, posing a challenge for the design of a selective inhibitor. We propose that the differences in the conformational dynamics among the TAM family members could potentially be exploited to achieve inhibitor selectivity for targeted receptors.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  enzyme inhibitor; protein dynamic; protein kinase; protein stability; protein structure

Mesh:

Substances:

Year:  2017        PMID: 28724631      PMCID: PMC5612104          DOI: 10.1074/jbc.M116.771485

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Tyro-3 family receptors are essential regulators of mammalian spermatogenesis.

Authors:  Q Lu; M Gore; Q Zhang; T Camenisch; S Boast; F Casagranda; C Lai; M K Skinner; R Klein; G K Matsushima; H S Earp; S P Goff; G Lemke
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

Review 2.  Phosphatidylserine recognition by phagocytes: a view to a kill.

Authors:  Yi Wu; Nitu Tibrewal; Raymond B Birge
Journal:  Trends Cell Biol       Date:  2006-03-10       Impact factor: 20.808

Review 3.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

4.  Structural basis for selective small molecule kinase inhibition of activated c-Met.

Authors:  Keith W Rickert; Sangita B Patel; Timothy J Allison; Noel J Byrne; Paul L Darke; Rachael E Ford; David J Guerin; Dawn L Hall; Maria Kornienko; Jun Lu; Sanjeev K Munshi; John C Reid; Jennifer M Shipman; Elizabeth F Stanton; Kevin J Wilson; Jonathon R Young; Stephen M Soisson; Kevin J Lumb
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

Review 5.  Axl kinase as a key target for oncology: focus on small molecule inhibitors.

Authors:  Clémence Feneyrolles; Aurélia Spenlinhauer; Léa Guiet; Bénédicte Fauvel; Bénédicte Daydé-Cazals; Pierre Warnault; Gwénaël Chevé; Aziz Yasri
Journal:  Mol Cancer Ther       Date:  2014-08-19       Impact factor: 6.261

6.  Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

Authors:  Alexis Mollard; Steven L Warner; Lee T Call; Mark L Wade; Jared J Bearss; Anupam Verma; Sunil Sharma; Hariprasad Vankayalapati; David J Bearss
Journal:  ACS Med Chem Lett       Date:  2011-12-08       Impact factor: 4.345

7.  Phagocytosis and clearance of apoptotic cells is mediated by MER.

Authors:  R S Scott; E J McMahon; S M Pop; E A Reap; R Caricchio; P L Cohen; H S Earp; G K Matsushima
Journal:  Nature       Date:  2001-05-10       Impact factor: 49.962

8.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

Authors:  Ted W Johnson; Paul F Richardson; Simon Bailey; Alexei Brooun; Benjamin J Burke; Michael R Collins; J Jean Cui; Judith G Deal; Ya-Li Deng; Dac Dinh; Lars D Engstrom; Mingying He; Jacqui Hoffman; Robert L Hoffman; Qinhua Huang; Robert S Kania; John C Kath; Hieu Lam; Justine L Lam; Phuong T Le; Laura Lingardo; Wei Liu; Michele McTigue; Cynthia L Palmer; Neal W Sach; Tod Smeal; Graham L Smith; Albert E Stewart; Sergei Timofeevski; Huichun Zhu; Jinjiang Zhu; Helen Y Zou; Martin P Edwards
Journal:  J Med Chem       Date:  2014-06-03       Impact factor: 7.446

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.

Authors:  Lin Pao-Chun; Perry M Chan; Wing Chan; Ed Manser
Journal:  J Biol Chem       Date:  2009-10-08       Impact factor: 5.157

View more
  5 in total

1.  Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors.

Authors:  Dominic J Lambo; Charlotta G Lebedenko; Paige A McCallum; Ipsita A Banerjee
Journal:  Mol Divers       Date:  2022-05-03       Impact factor: 2.943

2.  HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.

Authors:  Wenjing Li; Xiahui Xiong; Amro Abdalla; Salvador Alejo; Linyu Zhu; Fei Lu; Hong Sun
Journal:  J Biol Chem       Date:  2018-08-14       Impact factor: 5.157

3.  Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.

Authors:  Samuel H Myers; Carolin Temps; Douglas R Houston; Valerie G Brunton; Asier Unciti-Broceta
Journal:  J Med Chem       Date:  2018-02-21       Impact factor: 7.446

4.  Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.

Authors:  Xiaojia Niu; Katharina Rothe; Min Chen; Sarah Grasedieck; Rick Li; Sung-Eun Nam; Xiuyan Zhang; German E Novakovskiy; Ye-Hyeon Ahn; Irina Maksakova; Shenshen Lai; Hong Zhang; Jun Yan; Hong Liu; Yun Zhao; Depei Wu; Yubin Ge; Wyeth W Wasserman; Arefeh Rouhi; Florian Kuchenbauer; Calvin K Yip; Zaihui Zhang; Xiaoyan Jiang
Journal:  Blood       Date:  2021-07-01       Impact factor: 25.476

5.  Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity.

Authors:  Olga Cruz-López; Carolin Temps; Beatrice Longo; Samuel H Myers; Francisco Franco-Montalban; Asier Unciti-Broceta
Journal:  ACS Omega       Date:  2019-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.